Tonix Pharmaceuticals Holding Corp
TNXP
NASDAQ
Biotechnology
$12.71
USD
+0.21 (+1.68%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $214.39M
Volume 347.6K
Revenue
$29.10M
TTM
+196.0%
YoY
Gross Margin
84%
TTM
+186.4%
YoY
Net Income
$-159.67M
TTM
-96.1%
YoY
Operating Cash Flow
$-152.99M
TTM
-135.9%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 2.0 | 3.3 | 5.4 | 6.9 | 13.5 |
YoY Growth | -9.5% | +16.6% | +108.8% | +183.2% | +577.9% |
Cost of Revenue | 3.3 | 1.4 | 1.1 | 1.6 | 0.7 |
Gross Profit | -1.3 | 1.9 | 4.3 | 5.3 | 12.8 |
Selling, General & Administrative | 16.2 | 25.7 | 35.7 | 28.6 | 36.0 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 27.0 | 35.0 | 52.6 | 46.8 | 55.4 |
Operating Income | -28.3 | -33.1 | -48.3 | -41.5 | -42.5 |
EBITDA | -27.8 | -32.6 | -47.8 | -41.0 | -41.9 |
Other Income / Expense | -0.9 | -0.2 | 0.0 | -0.0 | 0.6 |
Total Other Income / Expense | 0.0 | 1.1 | 1.4 | 1.3 | 2.0 |
Income Before Income Taxes | -28.3 | -32.0 | -46.9 | -40.2 | -40.6 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -28.3 | -32.0 | -46.9 | -40.2 | -40.6 |
Consolidated Net Income / Loss | -28.3 | -32.0 | -46.9 | -40.2 | -40.6 |
Net Income Attributable to Common Shareholders | -28.3 | -32.0 | -46.9 | -40.2 | -40.6 |
Basic EPS | -$3.86 | -$3.59 | -$3.95 | -$2.93 | -$2.44 |
Diluted EPS | -$3.86 | -$3.59 | -$3.95 | -$2.93 | -$2.44 |
Basic Shares Outstanding | 7.3M | 8.9M | 11.9M | 13.7M | 16.6M |
Diluted Shares Outstanding | 7.3M | 8.9M | 11.9M | 13.7M | 16.6M |